Why Nkarta, Inc.’s (NKTX) Stock Is Down 5.39%
As of Monday, August 24, Nkarta, Inc.’s NKTX share price has dipped by 5.39%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Commentary & Analysis
Why Nkarta, Inc.’s (NKTX) Stock Is Up 5.06%
As of Friday, August 21, Nkarta, Inc.’s NKTX share price has surged by 5.06%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Nkarta, Inc.’s (NKTX) Stock Is Up 7.05%
As of Wednesday, August 19, Nkarta, Inc.’s NKTX share price has surged by 7.05%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Nkarta, Inc.’s (NKTX) Stock Is Down 7.93%
As of Tuesday, August 11, Nkarta, Inc.’s NKTX share price has dipped by 7.93%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Nkarta, Inc.’s (NKTX) Stock Is Up 6.78%
As of Thursday, August 06, Nkarta, Inc.’s NKTX share price has surged by 6.78%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | NKTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $193.4 | $282.5 | 27% |
|
| Shares Out (Mil) | 74.5 | 54.1 | 56% |
|
| Institutional Ownership | 99.4% | 92.9% | 88% |
|
| Float (Mil) | 60.5 | 41.5 | 52% |
|
| Beta | 0.94 | 0.94 | 56% |
|
| Avg Daily Volume (000s) | 545 | 469 | 61% |
|
| Price Change (52-week) |
27.4% | 59.1% | 70% |
|
| Growth | NKTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (2.6%) | (10.1%) | 36% |
|
| EPS (5yr) | 23.7% | 15.9% | 74 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (48.8%) | (15.6%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.383) | ($1.707) | ($1.753) | |
| Month Ago EPS | ($0.370) | ($1.480) | ($1.650) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | ($0.385) | ($1.520) | ($1.725) | |
| Year/Year Chg | (29.3%) | 21.3% | 14.1% | |
| Financials | NKTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($117) | ($43) | 10% |
|
| EPS (TTM) | ($1.581) | ($1.500) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($93) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($29) | $2 | 23% |
|
| Long-Term Debt (Q1) (Mil) | $66 | $4 | 41% |
|
| Enterprise Value (Q1) (Mil) | $58 | $195 | 17% |
|
| Valuation | NKTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.78 | 2.78 | 15% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NKTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (29.9%) | (47.6%) | 17% |
|
| ROE | (38.8%) | (55.0%) | 18% |
|
| Liabilities to Assets | 26.6% | 29.6% | 18% |
|
| F-Score | 1 | 3 | 1% |
|
Nkarta, Inc. did not pass any screens on 9/1/2026.
